Literature DB >> 16822699

Toxoplasma gondii grown in human cells uses GalNAc-containing glycosylphosphatidylinositol precursors to anchor surface antigens while the immunogenic Glc-GalNAc-containing precursors remain free at the parasite cell surface.

Nahid Azzouz1, Hosam Shams-Eldin, Sebastian Niehus, Françoise Debierre-Grockiego, Ulrike Bieker, Jörg Schmidt, Corinne Mercier, Marie-France Delauw, Jean-François Dubremetz, Terry K Smith, Ralph T Schwarz.   

Abstract

Toxoplasma gondii is a ubiquitous parasite that infects nearly all warm-blooded animals. Developmental switching in T. gondii, from the virulent tachyzoite to the relatively quiescent bradyzoite stage, is responsible for the disease propagation after alteration of the immune status of the carrier. The redifferentiation event is characterized by an over expression of a tachyzoite specific set of glycosylphosphatidylinositol anchored surface antigens and free GPIs. T. gondii grown in animal cells uses two glycosylphosphatidylinositol precursors to anchor the parasite surface proteins. The first form has an N-acetylgalactosamine residue bound to a conserved three-mannosyl core glycan, while the second structure contains an additional terminal glucose linked to the N-acetylgalactosamine side branch. Sera from persons infected with T. gondii reacted only with the glucose-N-acetylgalactosamine-containing structure. Here we report that T. gondii cultured in human cells uses predominantly the N-acetylgalactosamine-containing structure to anchor the parasite surface antigens. On the other hand, glycosylphosphatidylinositol structures having an additional terminal glucose are found exclusively on the parasite cell surface as free glycolipids participating in the production of cytokines that are implicated in the pathogenesis of T. gondii. We also provide evidence that such free glycosylphosphatidylinositols are restricted mainly to the lipid microdomains in the parasite cell surface membrane and mostly associated with proteins involved in the parasite motility as well as invasion of the host cell.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822699     DOI: 10.1016/j.biocel.2006.05.006

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  5 in total

1.  CRISPR/Cas9 and glycomics tools for Toxoplasma glycobiology.

Authors:  Elisabet Gas-Pascual; Hiroshi Travis Ichikawa; Mohammed Osman Sheikh; Mariam Isabella Serji; Bowen Deng; Msano Mandalasi; Giulia Bandini; John Samuelson; Lance Wells; Christopher M West
Journal:  J Biol Chem       Date:  2018-11-21       Impact factor: 5.157

2.  Mutations in PIGU Impair the Function of the GPI Transamidase Complex, Causing Severe Intellectual Disability, Epilepsy, and Brain Anomalies.

Authors:  Alexej Knaus; Fanny Kortüm; Tjitske Kleefstra; Asbjørg Stray-Pedersen; Dejan Đukić; Yoshiko Murakami; Thorsten Gerstner; Hans van Bokhoven; Zafar Iqbal; Denise Horn; Taroh Kinoshita; Maja Hempel; Peter M Krawitz
Journal:  Am J Hum Genet       Date:  2019-07-25       Impact factor: 11.025

Review 3.  N-Acetylglucosamine Sensing and Metabolic Engineering for Attenuating Human and Plant Pathogens.

Authors:  Sekhu Ansari; Vinay Kumar; Dharmendra Nath Bhatt; Mohammad Irfan; Asis Datta
Journal:  Bioengineering (Basel)       Date:  2022-02-05

4.  Virulent and avirulent strains of Toxoplasma gondii which differ in their glycosylphosphatidylinositol content induce similar biological functions in macrophages.

Authors:  Sebastian Niehus; Terry K Smith; Nahid Azzouz; Marco A Campos; Jean-François Dubremetz; Ricardo T Gazzinelli; Ralph T Schwarz; Françoise Debierre-Grockiego
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

5.  Detection of Anti-Toxoplasma gondii Antibodies in Human Sera Using Synthetic Glycosylphosphatidylinositol Glycans on a Bead-Based Multiplex Assay.

Authors:  Monika Garg; Daniel Stern; Uwe Groß; Peter H Seeberger; Frank Seeber; Daniel Varón Silva
Journal:  Anal Chem       Date:  2019-08-22       Impact factor: 6.986

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.